Cargando…
CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma
Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary brain tumor in adults. Current treatment options typically consist of surgery followed by chemotherapy or more frequently radiotherapy, however, median patient survival remains at just over 1 year. Therefore, the need...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185049/ https://www.ncbi.nlm.nih.gov/pubmed/34113233 http://dx.doi.org/10.3389/fnins.2021.662064 |